Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

Marc S Sabatine, Elliott M Antman, Petr Widimsky, Iftikhar O Ebrahim, Robert G Kiss, André Saaiman, Rostislav Polasek, Charles F Contant, Carolyn H McCabe, Eugene Braunwald

DOI: 10.1016/S0140-6736(09)61454-9

Klíčová slova: Acute Coronary Syndrome, Aged, Angioplasty, Balloon, Coronary, Anticoagulants, Coronary Angiography, Cyclic N-Oxides, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, Heparin, Humans, Infusions, Intravenous, Injections, Intravenous, Kaplan-Meier Estimate, Male, Middle Aged, Peptides, Platelet Aggregation Inhibitors, Pyridines, Safety, Treatment Outcome

Anotace: BACKGROUND: Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study. BACKGROUND: Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study. BACKGROUND: Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study. BACKGROUND: Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study. BACKGROUND: Otamixaban is an intravenous direct factor Xa inhibitor. We aimed to assess its efficacy and safety in non-ST-elevation acute coronary syndromes and to identify the optimum dose range for further assessment in a phase 3 study.

Uložit do Citace PRO